MedTrace Logo

Effect of Hilotherapy in the Management of Symptoms Related to Taxane-Associated Peripheral Neuropathy

NCT07345221 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-15

No results posted yet for this study

Summary

In this randomized controlled study, it was aimed to determine the effect of hilotherapy on quality of life and comfort level in the management of symptoms related to taxane-associated peripheral neuropathy in patients with breast cancer.

* The experimental and control group patients will answer the survey questions according to the data collection forms before the first chemotherapy course (To) and will undergo physical examinations by the researcher.
* In the experimental group, the Hilotherapy device will be connected and initiated 30 min before the chemotherap.
* The device will continue to cool for another 60 minutes when the chemotherapy ends.
* Both groups will continue to receive chemotherapy courses at the intervals determined as planned.
* Hilotherapy will be applied to the experimental group patients during each course according to the study protocol.
* For both groups, participants will answer the questions according to the data collection forms and will undergo physical examinations by the researcher after the 4th chemotherapy course (T1), 8th chemotherapy course (T2), 12th chemotherapy course (T3) and 4 weeks after the end of chemotherapy (T4).

Conditions

  • Peripheric Neuropathy

Interventions

DEVICE

Hilotherapy

Applying hilotherapy device at chemotherapy courses

Sponsors & Collaborators

  • Nuran Ayşen Pamir Aksoy

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-04
Primary Completion
2026-06-30
Completion
2026-08-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07345221 on ClinicalTrials.gov